CompletedNCT04819776
Iloperidone for acute mania or mixed episodes in bipolarity
About this title
Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder
Read the official source — NCT04819776Researchers compared Iloperidone and placebo to find out how the approaches affected manic symptoms in people with bipolarity type I during a manic episode.
Medication studyAges 18–65Multiple countries
Understand this study
What did researchers investigate?
Researchers compared Iloperidone and placebo to find out how the approaches affected manic symptoms in people with bipolarity type I during a manic episode.
Who was this study for?
This study was for people with type I bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Little Rock and 26 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: March 22, 2021
- Recruitment status
- Completed
- Enrollment listed in the registry
- 417
- Sponsor
- Vanda Pharmaceuticals
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Bulgaria, Poland
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT04819776
- Official title
Show the full official title
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Iloperidone for 4 Weeks in the Treatment of Patients With Acute Manic Episodes Associated With Bipolar I Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Little Rock, United States · Rogers, United States · Cerritos, United States
24 more locations
- Culver City, United States
- Long Beach, United States
- Orange, United States
- Torrance, United States
- Miami Lakes, United States
- Oakland Park, United States
- Atlanta, United States
- Decatur, United States
- Gaithersburg, United States
- Flowood, United States
- Las Vegas, United States
- Marlton, United States
- Dayton, United States
- North Canton, United States
- Austin, United States
- DeSoto, United States
- Richardson, United States
- Novi Iskar, Bulgaria
- Tserova Koria, Bulgaria
- Kardzhali, Bulgaria
- Lovech, Bulgaria
- Veliko Tarnovo, Bulgaria
- Vratsa, Bulgaria
- Tuszyn, Poland
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared Iloperidone and placebo to find out how the approaches affected manic symptoms in people with bipolarity type I during a manic episode.
Who is behind this study?
The study sponsor is Vanda Pharmaceuticals.
Did this study involve medication?
Yes. The study involved medication, including Iloperidone and Iloperidone Placebo.
Who was this study for?
This study was for people with type I bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
